Bacteria shed light on new drug targets for inherited cancers

Cancer Research UK scientists have succeeded in purifying a protein found in bacteria that could reveal new drug targets for inherited breast and ovarian cancers - and other cancers linked to DNA repair faults. The study is published in the journal Nature yesterday.

The team, based at Cancer Research UK’s Paterson Institute in Manchester, are the first to decipher the structure of a called PARG – which plays an important role in and acts in the same pathway as PARP.

PARP inhibitors have been showing great promise in clinical trials for patients with breast, ovarian and prostate cancers caused by mutations in genes called BRCA1 and BRCA2. They work by blocking the action of PARP – a protein that chemically tags areas of DNA damage to highlight them to the cell’s DNA repair machinery.

PARG removes these chemical tags after the DNA damage has been repaired. So the researchers believe that, similar to PARP inhibitors, drugs designed to block the action of PARG could be effective in treating cancer.

Lead author Dr. Ivan Ahel, based at Cancer Research UK’s Paterson Institute in Manchester, said: “For decades scientists have wanted to find out the structure of PARG, but its large size makes it very hard to produce in the lab. By studying a smaller version of PARG found in bacteria, we’ve been able to create a ‘3D map’ that researchers can use to understand more about how PARG works. The next step will be to investigate whether drugs that block its activity might be an effective way of treating cancers driven by faults in DNA repair genes.”

Dr. Julie Sharp, senior science information manager at Cancer Research UK, said: “This discovery shows that bacteria and humans share similarities in the cellular machinery they use to repair damaged DNA. Importantly, knowing the structure of PARG in could help researchers design targeted treatments that are also effective in cancer patients. We hope this will lead to further treatment options for patients with a range of cancers in the future.”

More information: Slade et al, The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase, Nature (2011). dx.doi.org/10.1038/nature10404

Related Stories

New test for ovarian cancer patients

Nov 09, 2010

Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the National Cancer Research Institute ...

Synthetic lethality: A new way to kill cancer cells

Feb 22, 2010

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports.

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

19 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

23 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.